Event Schedule
Have a look at Schedule
Welcome Coffee, Registration & Itinerary Collection
Opening Remarks
Amraj Dhillon
Key Account Manager
World BI
Chair Welcome Address
Gautam Hotti
Director Generative AI
Novartis
Presentation 1: Shifting Portfolio of Target Classes and Small Molecule Modalities within Hit Discovery
Jarrod Walsh
Director of Biochemical & Biophysical Screening
AstraZeneca
Presentation 2: The AI Revolution in Virtual Screening
Victor Guallar
CSO
Nostrum Biodiscovery
Presentation 3: Innovation Addressing Important Unmet Needs in Women’s Health
Marcel Van Duin
Chief Scientific Officer
Organon
Coffee Break & Networking Session
Presentation 4: Non Toxic Anti-inflammatory Monoterpens : Pro-drugs and Metabolites
Patrizia D'Alessio
CEO
AISA Therapeutics
Presentation 5: Bias in Medicinal Chemistry: The Kinase-phosphatase Mystery
Gerhard Müller
Chief Scientific Officer
SpiroChem AG
Presentation 6: The HIV Drug Resistance Challenge in Low and Middle Income Countries and How to Combat it
Dr. Catherine Kibirige
Senior Research Associate
Imperial College London
Presentation 7: Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Roman Blaszczyk
Associate Director Medicinal Chemistry, Principal Scientist
Molecure
Lunch Break
Presentation 8: Formulation Strategies at the Interface of Drug Discovery and Development
Philippe Lienard
Pre-Clinical Leader
Pasteur Institute
Presentation 9: Impact of Big Data and Artificial Intelligence in Drug Discovery and Development
Nick Brown
Executive Head of Imaging & Data Analytics (CPSS, R&D)
AstraZeneca
Presentation 10: Insights into the Mechanisms of EGFRi-induced Cutaneous Adverse Drug Reactions From Functional Phospho-proteomic and Transcriptomic Data
Dr. Georgios Stamatas
Research Associate Director, Essential Health Translational Science
Johnson & Johnson
Presentation 11: Expanding the Drug-gable Genome
Ulrich Hommel
Former Head Integrated Target and Lead Discovery
Novartis
Coffee Break & Networking Session
Presentation 12: Predicting the Future of our Medicines: Unleashing the Power of Novel Data and Omics Approaches for Indication Discovery and Expansion
Saleha Patel
Associate Principal Scientist - Emerging Innovations Unit
AstraZeneca
Presentation 13: Reasons; Why you Couldn't (and Shouldn't Anyway) Use Generic LLMs in the Drug Discovery Space
Guglielmo Iozzia
Associate Director - Data Science, ML/AI, Computer Vision
MSD
Presentation 14: Towards General AI
Ahmed Serag
Professor, Founder and Director, Artificial Intelligence and Innovation
Weill Cornell Medicine - Qatar (WCM-Q)
Closing Remarks
Gautam Hotti
Director Generative AI
Novartis
End of Day 1
Welcome Coffee, Registration & Itinerary Collection
Opening Remarks
Amraj Dhillon
Key Account Manager
World BI
Chair Welcome Address
Gautam Hotti
Director Generative AI
Novartis
Presentation 15: Using Chemical Language Approach to Improve the Quality of Life of Patients with SLE - Design and Development of Active and Selective PI3K inhibitor: CPL302415.
Mariola Stypik
Senior Specialist Medicinal Chemist
Celon Pharma
Presentation 16: 350 Years of Curiosity and Innovation
Dr. Ulrich A.K. Betz
Senior Vice President Innovation
Merck
Presentation 17: Recent Advances in the Discovery of RNA-Targeted Small Molecules
Jacques Dumas
Chief Scientific Officer
Arrakis Therapeutics
Coffee Break & Networking Session
Presentation 18: Use of Biophysics to Decipher New Mechanisms of Action in Drug Discovery
David Moreno Delgado
Associate Director Assay development and Technologies
Galapagos
Presentation 19: MZe786 is a Therapeutic and Preventive Molecule
Dr. Keqing Wang
Co-founder
MirZyme Therapeutics Limited
Presentation 20: The Search of New Drugs to Slow the Ageing Process
Jonathan Wingfield
Principal Scientist
AstraZeneca
Presentation 21: Latest Trends and Development of Allosteric Drugs
Manolo Bellotto
General Manager
Gain Therapeutics
Lunch Break
Presentation 22: Next-generation AI/ Machine Learning in Drug Discovery
Rabia Khan
Founder/CEO
Serna.bio
Presentation 23: Predicting Cell Viability in Cell and Gene Therapy Manufacturing
Gautam Hotti
Director Generative AI
Novartis
Presentation 24: Combining Robotics and Machine Learning to Accelerate Small Molecule Drug Discovery
Martin-Immanuel Bittner
Co-Founder & CEO
Arctoris
Presentation 25: Degrading Invisible Proteins: Releasing New Targets in Oncology and Beyond
Santiago Esteban Martin
Chief Executive Officer
IDP Discovery Pharma
Closing Remarks
Gautam Hotti
Director Generative AI